Long-Term Follow-Up and Recontact

Genetic results do not stay fixed. A variant of uncertain significance may be reclassified, a negative exome may become positive on reanalysis, and a condition without treatment may acquire one. This creates an obligation with no settled boundaries: someone counselled a decade ago may now be carrying information that is wrong, and the profession has not resolved whose job it is to tell them.

• Reclassification is common and runs in both directions. Variants of uncertain significance are reclassified over time, most often downward to likely benign, but upgrades to pathogenic occur and carry surveillance and cascade testing consequences.
• Reanalysis of negative exome and genome data yields new diagnoses at a meaningful rate as gene-disease relationships are established, and is a distinct service from repeat testing. It is generally worth considering at intervals of a year or more, and it is cheaper than resequencing.
• The duty to recontact is unresolved. Professional statements generally describe a shared responsibility rather than an absolute clinician duty, on the practical grounds that clinics cannot indefinitely track every patient, that contact information decays, and that the volume is unmanageable. This is an acknowledged compromise rather than a principled answer.
• Shift some responsibility to the patient, explicitly and in writing. Telling patients at the time of testing that classifications change, that they should check back periodically, and that they should keep their contact details current converts an impossible tracking problem into a shared one. It only works if it is said clearly and documented.
• Laboratories issue amended reports, but they go to the ordering clinician, who may have left, retired, or moved institutions. The amended report arriving at a defunct address is a common failure mode.
• The medical record is the durable artifact. A results letter in the chart, written so that a future clinician can understand what was tested and what it meant at the time, outlives the counselor and the clinic.
• Cascade testing decays over time. Relatives informed once often do not act, and uptake is well below what the counselor assumes. A single conversation is rarely sufficient, and follow-up on whether relatives were tested is part of the care.
• Life stage triggers recontact needs. Reproductive planning, a new diagnosis in the family, a child reaching adulthood, and the age at which surveillance should begin are all points at which someone counselled years earlier needs to return.
• Practical mechanisms include registries, patient portals that survive staff turnover, periodic reanalysis policies with defined intervals, and clear documentation of who is responsible for what.
• Say what you cannot do. Promising indefinite recontact that the clinic cannot deliver is worse than stating plainly that the patient should check in every few years.

• A woman tested in 2015 received a variant of uncertain significance and was told it was probably not important. It has since been reclassified as pathogenic. She was never recontacted because the ordering physician left the institution and the amended report went nowhere. Her sister develops the associated cancer, which surveillance might have caught. This is the failure mode the whole area exists to prevent.
• A child's exome was non-diagnostic four years ago. On reanalysis, a gene established as disease-causing in the interval explains the phenotype. Reanalysis of the existing data, not new sequencing, made the diagnosis.
• A counselor tells a patient at the time of testing that classifications change, that she should contact the clinic every two to three years, and that she should update her details if she moves. The instruction is documented and included in the results letter. Three years later she calls, and the reclassification is found.
• A man is told to inform his four siblings. Two years later the counselor's follow-up finds that only one was told, and that sibling did not pursue testing. Cascade uptake is consistently lower than counselors assume, and treating the initial conversation as completion overstates what happened.

• Do not describe a variant of uncertain significance as nothing to worry about. It may be reclassified, and dismissive framing at disclosure discourages the patient from ever checking back.
• Do not rely on the laboratory to reach the patient. Amended reports go to the ordering clinician, who may be unreachable.
• Do not promise recontact the clinic cannot deliver. Say what the system can actually do.
• Do not assume cascade testing happened. Follow up, because uptake is low.
• Do not treat reanalysis as the same as retesting. It is a distinct, cheaper service and is frequently not offered because nobody asked.